Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Adjuvant Colon Cancer w/ ELOXatin®/5 FU Based Regimen: ACCELOX

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01310972
Recruitment Status : Completed
First Posted : March 9, 2011
Last Update Posted : August 10, 2018
Sponsor:
Information provided by (Responsible Party):
King Faisal Specialist Hospital & Research Center

Brief Summary:
Adjuvant Colon Cancer With ELOXatin®/5 FU Based Regimen: ACCELOX

Condition or disease Intervention/treatment
Colon Cancer Other: Registry

Detailed Description:
It's a study of adjuvant colon carcinoma using ELOXatin/5-FU based chemotherapeutic regimen called ACCELOX as a definitive curative therapy.

Layout table for study information
Study Type : Observational
Actual Enrollment : 6 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Adjuvant Colon Cancer With ELOXatin®/5 FU Based Regimen: ACCELOX
Study Start Date : September 2007
Actual Primary Completion Date : September 2007
Actual Study Completion Date : September 2007

Intervention Details:
  • Other: Registry
    Registry


Primary Outcome Measures :
  1. OS, PFS, DFS [ Time Frame: For the duration of the experiment ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   14 Years to 85 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Colon Cancer Registry
Criteria

Inclusion Criteria:

  • Patients with Adjuvant Colon Cancer

Exclusion Criteria:

  • Patients with diagnosis other than Colon Cancer.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01310972


Locations
Layout table for location information
Saudi Arabia
Kfsh & Rc
Riyadh, Saudi Arabia
Sponsors and Collaborators
King Faisal Specialist Hospital & Research Center
Investigators
Layout table for investigator information
Principal Investigator: Al Jubran, M.D. KFSH & RC

Layout table for additonal information
Responsible Party: King Faisal Specialist Hospital & Research Center
ClinicalTrials.gov Identifier: NCT01310972     History of Changes
Other Study ID Numbers: RAC# 2071-027
RAC# 2071-027 ( Other Identifier: KFSH&RC IRB )
First Posted: March 9, 2011    Key Record Dates
Last Update Posted: August 10, 2018
Last Verified: August 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Keywords provided by King Faisal Specialist Hospital & Research Center:
Adjuvant Colon Cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Colonic Neoplasms
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Colonic Diseases
Digestive System Diseases
Gastrointestinal Diseases
Intestinal Diseases
Oxaliplatin
Antineoplastic Agents